NVCR Key Statistics, Chart & Performance
The current stock price of NVCR is 14.87 USD. In the past month the price increased by 17.09%. In the past year, price decreased by -45.83%.
NVCR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.29 | 219.41B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.95 | 207.41B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.35 | 145.84B | ||
| SYK | STRYKER CORP | 27.88 | 140.43B | ||
| BDX | BECTON DICKINSON AND CO | 14.23 | 58.56B | ||
| IDXX | IDEXX LABORATORIES INC | 56.49 | 56.88B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.91 | 49.08B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.21 | 40.16B | ||
| RMD | RESMED INC | 25.35 | 36.63B | ||
| DXCM | DEXCOM INC | 36.79 | 26.69B | ||
| PODD | INSULET CORP | 64.09 | 20.60B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.63 | 18.64B |
Related stock screener links
About NVCR
Company Profile
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The firm's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Company Info
NOVOCURE LTD
No. 4 The Forum, Grenville Street
Saint Helier JE2 4UF JE
CEO: Asaf Danziger
Employees: 1488
Phone: 441534756700
NOVOCURE LTD / NVCR FAQ
What does NVCR do?
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The firm's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
What is the stock price of NOVOCURE LTD today?
The current stock price of NVCR is 14.87 USD. The price increased by 3.19% in the last trading session.
What is the dividend status of NOVOCURE LTD?
NVCR does not pay a dividend.
What is the ChartMill rating of NOVOCURE LTD stock?
NVCR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about NOVOCURE LTD (NVCR) stock?
13 analysts have analysed NVCR and the average price target is 25.28 USD. This implies a price increase of 70.02% is expected in the next year compared to the current price of 14.87.
What is the Price/Earnings (PE) ratio of NOVOCURE LTD (NVCR)?
NOVOCURE LTD (NVCR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.61).
Can you provide the short interest for NVCR stock?
The outstanding short interest for NOVOCURE LTD (NVCR) is 6.89% of its float.
NVCR Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to NVCR. When comparing the yearly performance of all stocks, NVCR is a bad performer in the overall market: 84.88% of all stocks are doing better.
NVCR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVCR. Both the profitability and financial health of NVCR have multiple concerns.
NVCR Financial Highlights
Over the last trailing twelve months NVCR reported a non-GAAP Earnings per Share(EPS) of -1.61. The EPS decreased by -15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.05% | ||
| ROE | -52.05% | ||
| Debt/Equity | 2.21 |
NVCR Forecast & Estimates
13 analysts have analysed NVCR and the average price target is 25.28 USD. This implies a price increase of 70.02% is expected in the next year compared to the current price of 14.87.
For the next year, analysts expect an EPS growth of 9.53% and a revenue growth 8.7% for NVCR